Results 51 to 60 of about 9,723,781 (298)

Establishment of cumulative assessment groups of pesticides for their effects on the nervous system

open access: yesEFSA Journal, 2019
Cumulative assessment groups of pesticides have been established for five effects on the nervous system: brain and/or erythrocyte acetylcholinesterase inhibition, functional alterations of the motor, sensory and autonomic divisions, and histological ...
European Food Safety Authority (EFSA)   +8 more
doaj   +1 more source

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk   +10 more
wiley   +1 more source

20220110_RAG_Risk assessment pandemic law_NL

open access: yes, 2022
RAG RA pandemic law 10-01 ...
Risk Assessment Group
core  

Fate and cumulative risk assessment of typical pesticides in celery cultivated in summer cool open fields

open access: yesEcotoxicology and Environmental Safety
This study evaluated residue dynamics, dissipation kinetics, and cumulative dietary risk of typical pesticides (imidacloprid, acetamiprid, thiamethoxam, pymetrozine, difenoconazole) on celery in summer cool-climate open fields, alongside compatibility of
Le SONG   +6 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Advancing the Contribution of Occupational Epidemiology to Risk Assessment [PDF]

open access: yes, 2011
The identification and quantification of risk factors that are characterized by low exposure levels, moderately increased risks, and unspecific exposure-disease relations is a major challenge facing risk assessment today.
Vlaanderen, J.J.   +2 more
core   +1 more source

National risk assessment 2023

open access: yes, 2023
The purpose of the national risk assessment is to anticipate relatively sudden incidents potentially targeted at Finland that call for activities deviating from the norm from authorities or even requesting help from other countries.

core   +1 more source

Cumulative dietary risk characterisation of pesticides that have chronic effects on the thyroid

open access: yesEFSA Journal, 2020
A retrospective chronic cumulative risk assessment of dietary exposure to pesticide residues, supported by an uncertainty analysis based on expert knowledge elicitation, was conducted for two effects on the thyroid, hypothyroidism and parafollicular cell
European Food Safety Authority (EFSA)   +10 more
doaj   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman   +9 more
wiley   +1 more source

Challenges of quantitative microbial risk assessment at EU level. [PDF]

open access: yes, 2009
Quantitative microbial risk assessment (QMRA) aims to model the fate of pathogenic micro-organisms along the food chain and the associated health risks.
Evers, E.G.   +4 more
core  

Home - About - Disclaimer - Privacy